Shares of Aileron Therap (NASDAQ:ALRN) have received an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus target price of $19.33 for the company and are forecasting that the company will post ($0.43) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aileron Therap an industry rank of 123 out of 265 based on the ratings given to related companies.

ALRN has been the topic of a number of research analyst reports. Jefferies Group LLC initiated coverage on Aileron Therap in a report on Monday, July 24th. They issued a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity initiated coverage on Aileron Therap in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 price target on the stock. Bank of America Corporation initiated coverage on Aileron Therap in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 price target on the stock. Finally, William Blair initiated coverage on Aileron Therap in a report on Monday, July 24th. They issued an “outperform” rating on the stock.

In other Aileron Therap news, Director Reinhard J. Ambros purchased 266,667 shares of the stock in a transaction that occurred on Wednesday, July 5th. The shares were bought at an average cost of $15.00 per share, with a total value of $4,000,005.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Lilly Ventures Fund I. Llc purchased 250,000 shares of the stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $3,750,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 696,667 shares of company stock worth $10,450,005.

A hedge fund recently bought a new stake in Aileron Therap stock. Candriam Luxembourg S.C.A. purchased a new position in Aileron Therap (NASDAQ:ALRN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 150,000 shares of the company’s stock, valued at approximately $1,673,000. Candriam Luxembourg S.C.A. owned about 1.02% of Aileron Therap at the end of the most recent reporting period.

Shares of Aileron Therap (NASDAQ ALRN) opened at 12.48 on Wednesday. Aileron Therap has a 52 week low of $10.73 and a 52 week high of $14.32. The company has a 50-day moving average of $12.92 and a 200-day moving average of $12.92. The stock’s market capitalization is $183.58 million.

TRADEMARK VIOLATION NOTICE: “Zacks: Aileron Therap (ALRN) Receives Average Rating of “Strong Buy” from Analysts” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/08/12/zacks-aileron-therap-alrn-receives-average-rating-of-strong-buy-from-analysts-updated.html.

About Aileron Therap

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therap (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therap and related companies with Analyst Ratings Network's FREE daily email newsletter.